<DOC>
	<DOCNO>NCT02036723</DOCNO>
	<brief_summary>GALATIR double blind randomize clinical trial compare efficacy safety BCD-021 ( bevacizumab ) Lucentis® ( ranibizumab ) patient neovascular wet age-related macular degeneration . The purpose study demonstrate non-inferiority efficacy safety BCD-021 compare Lucentis® .</brief_summary>
	<brief_title>Safety Efficacy Study BCD-021 Compared Lucentis® Patients With Neovascular Wet Age-related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Having sign write informed consent form ; Men woman ; Patients must 50 ; Wet AMD study eye , define : Not previously treat active choroidal neovascular membrane ( CNV ) , include retinal angiomatous proliferation ( RAP ) , oedema involve fovea demonstrate optical coherence tomography ( OCT ) fluorescein angiography ( FA ) . FA shall older 14 day randomization ; Best correct VA study eye range 20/32 ( 6.3/10 ) 20/320 ( 0.6/10 ) EDTRS scale ; Size lesion &lt; 12 disk area ; In case occult neovessels , proof require recent development lesion : loss VA least 5 letter EDTRS ( equivalent one line ) last 3 month OR appearance subretinal hemorrhage OR increase size lesion ( &gt; 10 % ) use fluorescein angiography last month comparison last 3 month OR appearance OCT criterion macular oedema type , serous separation neuroepithelium , separation pigment epithelial last month ; Only one eye study patient may recruit study . If nonstudy eye treat antiVEGF therapy , develop wet AMD , drug use study eye shall use nonstudy eye . Treatment must give doubleblind nonstudy eye well ; Patient 's ability ( Investigator 's opinion ) follow protocol procedure ; Male female patient normal reproductive function sexual partner aware willing use voluntarily reliable method contraception whole period study include screening period . This requirement apply patient underwent operative sterilization define postmenopausal ( confirmed medical history documentation ) within last 2 year . Reliable method contraception suggest use 1 barrier method combination 1 follow method : spermicide , intrauterine device etc . Previous current treatment intravitreal injection antiVEGF drug ( ranibizumab , bevacizumab , aflibercept pegaptanib , etc . ) study eye ; Other heal treatment study eye last 3 month first injection ; Former vitrectomy study eye ; ; Medical history photocoagulation study eye ; Involvement another clinical study ( study eye and/or eye ) ; Subretinal haemorrhage reach fovea centre , size &gt; 50 % lesion area ; Fibrosis retrofoveal retinal atrophy study eye ; Retinal pigment epithelial tear reach macula study eye ; Choroidal neovascularisation relate AMD study eye ; Medical history intravitreal medical device study eye ; Active suspect ocular periocular infection ; Acute conjunctivitis , keratitis , scleritis , endophthalmitis ; Serious active intraocular inflammation study eye ; Maculaforamen study eye ; Myopia large 8 diopter ; Former corneal graft study eye ; Medical history autoimmune idiopathic uveitis ; Proved diabetic retinopathy ; Intraocular pressure ≥ 25 mmHg despite two topical hypotonic treatment ; Medical history intraocular surgery within 2 month first injection study eye ; Aphakia lack lens capsule ( remove laser ) study eye ; Any illness ocular condition would require intraocular surgery study eye within 12 month inclusion ; Known hypersensitivity ranibizumab , bevacizumab , another drug composite medicinal product use ; allergy fluorescein , indocyanine green , anaesthetic eye drop ; Arterial hypertension control appropriate treatment ; Previous current treatment systemic administration bevacizumab ; Pregnancy breastfeeding ; Any determine immunodeficiency ; Syphilis , HIV , hepatitis B , history hepatitis C virus ; Any mental disorder , include major depression and/or suicidal thought anamnesis , Investigator 's opinion , create risk patient influence patient 's ability follow study protocol ; Drug addiction , alcoholism . Presence history malignant neoplasm ( include lymphoproliferative disease ) , exception : Adequately treat basal cell carcinoma cervical carcinoma situ ; Any malignancy complete remission 5 year ; Simultaneous participation clinical trial , well former participation clinical trial within 3 month study initiation ; previous participation study</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Macular Degeneration</keyword>
	<keyword>Eye Diseases</keyword>
	<keyword>Neovascular Macular Degeneration</keyword>
	<keyword>Choroidal Neovascularization</keyword>
	<keyword>Geographic Atrophy</keyword>
</DOC>